-transparent.png){kind=logo}
The effects of captopril have been studied in 10 patients suffering from chronic obstructive pulmonary disease (COPD) with moderate essential hypertension. Captopril was given as monotherapy (75-100 mg/day) over a period of 60 days. The following effects of captopril were seen in these patients: a significant reduction of systolic blood pressure (P less than 0.01) and of diastolic blood pressure (P less than 0.001), both in the supine and in the standing position; a significant increase of the vital capacity (P less than 0.05); no significant change in other various respiratory function tests or of heart rate, and no side effects, including bronchospasm in the patients sensitive to bronchodilator drugs. The present data suggest that in COPD patients with essential hypertension, captopril is an effective hypotensive agent and has no adverse effects in pulmonary function.
L Bertoli, and
M Fusco, and
E Micallef, and
I Busnardo
March 1988,
Postgraduate medical journal,
L Bertoli, and
M Fusco, and
E Micallef, and
I Busnardo
August 1993,
Zhonghua nei ke za zhi,
L Bertoli, and
M Fusco, and
E Micallef, and
I Busnardo
November 1979,
Chest,
L Bertoli, and
M Fusco, and
E Micallef, and
I Busnardo
January 2020,
Frontiers in pharmacology,
L Bertoli, and
M Fusco, and
E Micallef, and
I Busnardo
January 1986,
Respiration; international review of thoracic diseases,
L Bertoli, and
M Fusco, and
E Micallef, and
I Busnardo
February 1989,
Arquivos brasileiros de cardiologia,
L Bertoli, and
M Fusco, and
E Micallef, and
I Busnardo
March 2016,
Kardiologiia,
L Bertoli, and
M Fusco, and
E Micallef, and
I Busnardo
June 2019,
Chinese medical journal,
L Bertoli, and
M Fusco, and
E Micallef, and
I Busnardo
January 2010,
The Indian journal of chest diseases & allied sciences,
L Bertoli, and
M Fusco, and
E Micallef, and
I Busnardo
January 1988,
Zeitschrift fur Erkrankungen der Atmungsorgane,
